Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Halozyme Therapeutics Inc has a consensus price target of $56.5 based on the ratings of 14 analysts. The high is $71 issued by JMP Securities on May 8, 2024. The low is $42 issued by SVB Leerink on March 16, 2023. The 3 most-recent analyst ratings were released by Benchmark, HC Wainwright & Co., and TD Cowen on August 8, 2024, August 8, 2024, and August 7, 2024, respectively. With an average price target of $63.33 between Benchmark, HC Wainwright & Co., and TD Cowen, there's an implied -0.26% downside for Halozyme Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Halozyme Therapeutics (NASDAQ:HALO) was reported by Benchmark on August 8, 2024. The analyst firm set a price target for $60.00 expecting HALO to fall to within 12 months (a possible -5.51% downside). 36 analyst firms have reported ratings in the last year.
The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Benchmark, and Halozyme Therapeutics reiterated their buy rating.
The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.
The last downgrade for Halozyme Therapeutics Inc happened on June 7, 2024 when Piper Sandler changed their price target from $48 to $51 for Halozyme Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $60.00 to $60.00. The current price Halozyme Therapeutics (HALO) is trading at is $63.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.